摘要
背景:腹主动脉瘤(AAA)是一种慢性退行性炎症性疾病,遗传、环境、生活方式等多种因素决定了动脉瘤的发生和发展。目前,外科治疗仍然是唯一有效的动脉瘤治疗方法,但目前尚无药物治疗可以限制AAAS的进一步扩大和胎儿的破裂。 目的:综述血管紧张素Ⅱ(AngⅡ)及其1型受体(AT1)在AAA发病机制中的作用及AT1受体阻滞剂(ARB)治疗临床AAA的可能机制。 结果:虽然许多途径或分子与AAA的形成和进展有关,但越来越多的证据表明肽激素AngⅡ及其受体AT1在AAA发病中最重要,提示AT1靶向抑制在治疗临床AAA疾病中具有重要的借鉴价值。本文综述了AT1缺乏症和药理学arb治疗对实验性AAAs的影响,并讨论了AAA患者用药是否及如何改变临床AAAS的自然过程,包括动脉瘤增大率、破裂率和AAA特异性死亡率,并提供了两个已登记的临床试验资料,即替米沙坦和缬沙坦在限制小型AAA增大方面的疗效。 结论:AngⅡ/AT1通路在动脉瘤的发病过程中起着重要作用,通过ARB靶向AT1有助于建立限制小AAAS持续增大的新的药理治疗方法。
关键词: 腹主动脉瘤,血管紧张素Ⅱ1型受体,血管紧张素受体阻滞剂,动脉瘤发病机制,血管外科,药物治疗。
图形摘要
Current Drug Targets
Title:Pathogenic and Therapeutic Significance of Angiotensin II Type I Receptor in Abdominal Aortic Aneurysms
Volume: 19 Issue: 11
关键词: 腹主动脉瘤,血管紧张素Ⅱ1型受体,血管紧张素受体阻滞剂,动脉瘤发病机制,血管外科,药物治疗。
摘要: Background: Abdominal aortic aneurysm (AAA) is a chronic degenerative inflammatory disease. Multi-factors including genetic, environmental and lifestyle factors determine the onsets and progression of AAAs. Currently surgical repair remains the only effective aneurysm treatment, but no pharmacological therapy is available for limiting further enlargement of small AAAs and fetal rupture.
Objective: This article is to review our current understanding of angiotensin II (Ang II) and its type 1 receptor (AT1) in AAA pathogenesis as well as the translational potential of AT1 receptor blocker (ARB) treatment for treating clinical AAA disease.
Results: While many pathways or molecules have been shown to associate with AAA formation and progression, accumulating evidence indicates the most significant importance of peptide hormone Ang II and its receptor AT1 in AAA pathogenesis and suggests the translational value of targeting inhibition of AT1 in treating clinical AAA disease. This review summarized the influences of AT1 deficiency and pharmacological ARB treatment on experimental AAAs. A discussion has also been made on whether and how ARB medication in AAA patients changes the natural course of clinical AAAs, including aneurysm enlargement rate, rupture and AAA-specific mortality. Additionally, we provided information on two registered clinical trials which are to test the efficacy of telmisartan and valsartan in limiting small AAA enlargement.
Conclusion: Ang II/AT1 pathway plays a critical role in aneurysmal pathogenesis. Targeting AT1 via ARB will help establishing novel pharmacological therapies for limiting continuous enlargement of small AAAs in patients.
Export Options
About this article
Cite this article as:
Pathogenic and Therapeutic Significance of Angiotensin II Type I Receptor in Abdominal Aortic Aneurysms, Current Drug Targets 2018; 19 (11) . https://dx.doi.org/10.2174/1389450119666180122155642
DOI https://dx.doi.org/10.2174/1389450119666180122155642 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Impact of Mast Cell Chymase on Renal Disease Progression
Current Hypertension Reviews Meet Our Editorial Board Member
Current Medical Imaging Osteopontin; as a Target Molecule for the Treatment of Inflammatory Diseases
Current Drug Targets Bridging Innate Immunity and Myocardial Ischemia/Reperfusion Injury: The Search for Therapeutic Targets
Current Pharmaceutical Design MicroRNAs as Biomarkers for Birth Defects
MicroRNA Editorial [Hot Topic: Experimental Models for the Study of Drugs Used to Prevent and Treat Vascular Diseases (Executive Editors: C.S. Thompson, D.P. Mikhailidis and K.I. Paraskevas)]
Current Pharmaceutical Design Current Understanding of the Molecular Mechanism between Hemodynamic- Induced Intracranial Aneurysm and Inflammation
Current Protein & Peptide Science Proinflammatory Gene Polymorphisms and Ischemic Stroke
Current Pharmaceutical Design Pharmacological Regulation of Dyslipoproteinaemia in Insulin Resistant States
Current Vascular Pharmacology Oxidative Stress and Lipid Peroxidation in Prolonged Users of Methamphetamine
Drug Metabolism Letters Measurement of Physical Changes in the Myocardium for Development of Novel Methods for Diagnosing Ischemia
Current Cardiology Reviews Vascular Risk Factors, Vascular Diseases, and Imaging Findings in a Hospital-based Cohort of Mild Cognitive Impairment Types
Current Alzheimer Research Drug Therapy for Abdominal Aortic Aneurysms Utilizing Omega-3 Unsaturated Fatty Acids and Their Derivatives
Current Drug Targets Vitamin D Metabolites and/or Analogs: Which D for Which Patient?
Current Vascular Pharmacology Coronary Magnetic Resonance Imaging
Current Pharmaceutical Design Screening for and Optimal Management of Small Abdominal Aortic Aneurysms: The Quest Continues
Current Vascular Pharmacology Preface
Recent Patents on Medical Imaging Adenosine Myocardial Perfusion Imaging
Current Medical Imaging Characteristics and Risk Factors Associated with Stroke Subtypes among Adult Patients Admitted to the Stroke Unit of Jimma University Medical Center: A Retrospective Cross-sectional Study
Current Hypertension Reviews Peripheral Arterial Disease: The Magnitude of the Problem and its Socioeconomic Impact
Current Drug Targets - Cardiovascular & Hematological Disorders